Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-10
2006-01-10
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S173000, C514S175000, C514S381000, C514S234800, C514S259500, C514S340000, C514S359000, C514S210030, C514S307000
Reexamination Certificate
active
06984633
ABSTRACT:
A therapeutic method is described for treating cardiofibrosis or cardiac hypertrophy using a combination therapy comprising a therapeutically-effective amount of an angiotensin II receptor antagonist and a therapeutically-effective amount of expoxymexrenone.
REFERENCES:
patent: 4559332 (1985-12-01), Grob et al.
patent: 5350752 (1994-09-01), Poss et al.
patent: 5380719 (1995-01-01), Kim
patent: 5401736 (1995-03-01), Enari et al.
patent: 5466704 (1995-11-01), Poss
patent: 5525614 (1996-06-01), Blankley et al.
patent: 0122232 (1984-10-01), None
patent: 0481448 (1991-04-01), None
patent: WO 9112001 (1991-08-01), None
patent: WO 9115206 (1991-10-01), None
patent: WO 9409778 (1994-05-01), None
patent: WO 9515166 (1995-06-01), None
Schrieber et al. “Failure of the aldosterone antagonist spironolactone to inhibit myocardial hypertrophy produced by . . . ,” Physiologia Bohemoslovaca, 1980, vol. 29, No. 6, pp. 577-579, Medline Abstract, AN 81151365.
CAPlus Abstract, AN: 1995:386737, Katayama et al., 1995.
Brilla et al., J. Mol. Cell. Cardiol., vol. 25, p. 563-575, 1993.
Gasparo et al., J. Pharm. Exp. Ther., vol. 240(2), p. 650-656, 1987.
The Journal of Steroid Biochemistry, vol. 32, No. 1b, 1989, pp. 223-227, De Gasparo et al., “Antialdosterone: Incidence and Prevention of Sexual Side Effects”.
The Journal of Pharmacology and Experimental Therapeutics, vol. 240, No. 2, 1987, pp. 650-656, De Gasparo et al.: “Three New Epoxy-Spirolactone Derivatives: Characterization in Vivo and in Vitro”.
Egan James J.
McMahon Ellen G.
Olins Gillian M.
Schuh Joseph R.
Ashbrook Charles
G.D Searle & Co.
Schuh Joseph R.
Wang Shengjun
LandOfFree
Method to treat cardiofibrosis with a combination therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to treat cardiofibrosis with a combination therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to treat cardiofibrosis with a combination therapy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3546405